Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-06-28 02:01 UTC

BIOMED PULSE

Daily Briefing on Longevity, Viruses & New Cures

Sunday, June 28, 2026

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has reached 896 confirmed cases and 232 deaths as of June 17, and remains a WHO-declared PHEIC — the dominant global health emergency right now. [1]

Alongside Ebola, a fresh Nipah case in Kerala, an active Andes hantavirus cluster from the M/V Hondius cruise ship, and a new Yellow Fever global update paint a tense but monitored infectious disease landscape heading into summer 2026. [2] [3] [4]

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS - DRC AND UGANDA (PHEIC)

  • As of June 17, 2026, a cumulative 896 confirmed cases and 232 deaths have been reported from DRC, with cross-border transmission into Uganda continuing. [1]
  • WHO declared the Bundibugyo virus disease (BVD) outbreak a Public Health Emergency of International Concern on May 17, 2026; the IHR Emergency Committee confirmed it does not yet meet the threshold for a pandemic emergency. [5] [6]
  • Africa CDC and WHO launched a joint continental Ebola response plan on June 5, 2026, aiming to raise US$518 million to support African countries in preparedness and response. [7]
  • WHO released its first comprehensive clinical management guidelines covering all Ebola and Marburg filovirus types on June 17, 2026, directly timed to the DRC outbreak. [8]
  • WHO convened expert groups on May 28, 2026 to assess candidate vaccines and therapeutics specifically for Bundibugyo virus, for which no approved countermeasures yet exist. [9]
  • CDC activated enhanced Ebola airport screening at Washington-Dulles International Airport on May 21, 2026, expanding to Atlanta Hartsfield-Jackson on May 23, 2026. [10]
  • The most recent CDC transcript update on the DRC and Uganda Ebola outbreak was posted June 26, 2026, confirming active response coordination remains ongoing.

NIPAH VIRUS - INDIA (KERALA)

  • On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district; the adult male developed neurological symptoms on May 30, 2026 and was hospitalized June 10, 2026. [2]
  • This follows two earlier NiV cases confirmed in West Bengal healthcare workers in January 2026 and one case in Rajshahi Division, Bangladesh in February 2026.

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The fourth WHO Disease Outbreak News on the Andes hantavirus cluster was published May 28, 2026, with additional confirmed cases added since the May 13 update; the outbreak originated aboard the M/V Hondius cruise ship reported to WHO on May 2, 2026. [4]
  • WHO Director-General publicly thanked the people of Tenerife on May 14, 2026 for their cooperation in safely disembarking over 120 passengers from 23 countries during the outbreak response.
  • CDC's most recent hantavirus response transcript update was issued June 24, 2026, signaling continued active monitoring of discharged passengers.

YELLOW FEVER - GLOBAL

  • WHO's June 24, 2026 global update reports 79 human yellow fever infections across six countries from January 1 to May 26, 2026, following elevated transmission activity in the Americas throughout 2025. [3]
  • Yellow fever is spread by infected Aedes and Haemagogus mosquitoes; WHO urges travelers to affected areas in Africa and the Americas to ensure vaccination. [3]

MERS-CoV AND OTHER ONGOING RISKS

  • WHO's December 2025 MERS-CoV global update recorded 19 cases including 4 deaths since the start of 2025, with 17 cases from Saudi Arabia and 2 from France.
  • A recombinant mpox strain combining genomic elements of clades Ib and IIb was documented globally as of February 2026 — WHO noted recombination is a known natural process but flagged the need for enhanced surveillance.
  • Avian influenza A(H9N2) was confirmed in an adult male in Italy on March 21, 2026 after return from Senegal, representing an isolated zoonotic spillover.
  • Measles has spread to 58 of 64 districts in Bangladesh as of April 2026, with 19,161 suspected cases and 2,897 laboratory-confirmed cases nationwide.

CDC ACIP MEETING - JUNE 25-26, 2026

  • CDC's Advisory Committee on Immunization Practices (ACIP) convened June 25-26, 2026 and concluded with a joint statement; full agenda and presentations are posted online.

🧬 LONGEVITY & AGING

CELLULAR SENESCENCE AND KIDNEY REPAIR

  • A study published in Renal Failure (June 2026) found that AMD1-mediated polyamine metabolism governs whether injured kidney tubular cells repair themselves or enter a senescent, non-recovering state — suggesting polyamine pathways as a potential therapeutic target to limit post-injury kidney aging.

MUSCLE AGING AND THE NUCLEUS AS MECHANOBIOLOGICAL HUB

  • Research published in Nucleus (June 18, 2026) by Esen, Battey, Stroud, and Kirby proposes that the cell nucleus acts as a critical mechanical sensor in aging muscle, integrating physical forces to regulate gene expression changes that drive age-related muscle decline (sarcopenia).

CARTILAGE CELLS AND SENESCENCE-INDEPENDENT DECLINE

  • A study in Regenerative Therapy (June 13, 2026) identified a conserved nine-gene decline module in long-term expanded auricular chondrocytes that drives loss of cell identity independently of senescence — pointing to a separate, non-senescence aging pathway in connective tissue.

INSULIN RESISTANCE AND MILD COGNITIVE IMPAIRMENT

  • Published in the Scandinavian Journal of Primary Health Care (June 23, 2026), Rotonen et al. found an association between insulin resistance and mild cognitive impairment in aging populations, reinforcing the metabolic-brain aging connection and the importance of blood sugar management for cognitive longevity.

DELIRIUM AS A BRIDGE BETWEEN INFECTION AND DEMENTIA

  • Two commentaries in Lancet Healthy Longevity (by Sipilä and Kivimäki; and by Penfold, Jiwaji, and MacLullich) propose that delirium — acute brain confusion common during severe infections — may be a mechanistic link between systemic infection and later development of dementia, opening a new prevention window.

GUT-DERIVED UREMIC TOXINS AND MULTI-ORGAN AGING

  • Xu, Snelson, and Marques published in Gut Microbes (June 15, 2026) examining how cardiovascular-kidney-metabolic syndrome is worsened by gut-derived uremic toxins, highlighting the gut microbiome as a modifiable driver of multi-organ aging.

HANDGRIP STRENGTH AND DIGESTIVE DISEASE RISK

  • A large prospective study in Global Health Action (June 15, 2026) found that combined handgrip strength predicted incident chronic digestive diseases in both Chinese and European older adults — reinforcing grip strength as a practical biomarker of systemic aging resilience.

CHRONIC KIDNEY DISEASE AND MULTIMORBIDITY MORTALITY

  • The NURTuRE-CKD multicentre cohort study published in Annals of Medicine (June 23, 2026) showed that multiple long-term conditions significantly accelerate mortality, progression to kidney failure, and reduce quality of life in CKD patients — underscoring comorbidity burden as central to aging outcomes.

💊 NEW CURES & APPROVALS

  • TRODELVY (sacituzumab govitecan-hziy), sponsor Immunomedics Inc, received a supplemental FDA approval (BLA761115), expanding its antibody-drug conjugate indication in cancer — the payload delivers SN-38 (a topoisomerase I inhibitor) directly to tumor cells.
  • KEYTRUDA (pembrolizumab), sponsor Merck Sharp Dohme, received a supplemental FDA approval (BLA125514) — the PD-1 immune checkpoint inhibitor continues to expand its indications across multiple tumor types.
  • KEYTRUDA QLEX (pembrolizumab plus berahyaluronidase alfa-pmph), sponsor Merck Sharp Dohme, received a supplemental FDA approval (BLA761467) — this subcutaneous co-formulation uses hyaluronidase to enable faster under-the-skin delivery of pembrolizumab.
  • IBRANCE (palbociclib), sponsor Pfizer, received supplemental approvals under both NDA212436 and NDA207103 — the CDK4/6 inhibitor targets cell cycle dysregulation in hormone receptor-positive breast cancer.
  • TRYNGOLZA autoinjector (olezarsen sodium), sponsor Ionis Pharmaceuticals Inc, received a supplemental FDA approval (NDA218614) — olezarsen is an antisense oligonucleotide that reduces apolipoprotein C-III to lower triglycerides.
  • SPRAVATO (esketamine hydrochloride), sponsor Janssen Pharmaceuticals, received a supplemental FDA approval (NDA211243) — the intranasal NMDA receptor antagonist is used for treatment-resistant depression.
  • RINVOQ LQ (upadacitinib), sponsor AbbVie, received a supplemental FDA approval (NDA218347) — the JAK1-selective inhibitor is used for inflammatory conditions including rheumatoid arthritis and atopic dermatitis.
  • RIFAPENTINE, sponsor Macleods Pharmaceuticals Ltd, received an original FDA approval (ANDA217042) as a generic — the rifamycin antibiotic is used in tuberculosis treatment regimens.
  • PROLIA (denosumab), sponsor Amgen, received a supplemental FDA approval (BLA125320) — the RANK-L inhibitor reduces bone resorption and is used to treat osteoporosis, relevant to bone aging.

🧪 CLINICAL TRIALS

ALZHEIMER'S DISEASE - TABLET-BASED REMOTE COGNITIVE TRAINING

  • Trial NCT07521865, registered June 26, 2026 on ClinicalTrials.gov, is assessing feasibility and usability of a tablet-based cognitive training program targeting specific cognitive components in older adults with Mild Cognitive Impairment (MCI) and early Alzheimer's disease, delivered via remote tele-health.

LUNG TRANSPLANT REJECTION - FOSTAMATINIB (SIMILAR TRIAL)

  • Trial NCT06948097 (SIMILAR), registered June 26, 2026, evaluates the safety and tolerability of fostamatinib — a Syk kinase inhibitor that blocks antibody-mediated immune signaling — in lung transplant patients with donor-specific antibodies, targeting a major cause of transplant failure and shortened lifespan post-transplant.

NSCLC EPIGENETIC-IMMUNOTHERAPY - INHALED AZACYTIDINE PLUS DURVALUMAB (AZA-AEGEAN)

  • Trial NCT06694454 (AZA-AEGEAN), registered June 26, 2026, tests neoadjuvant inhaled azacytidine (a DNA methylation inhibitor) combined with platinum-based chemotherapy and durvalumab (anti-PD-L1) in operable early-stage non-small cell lung cancer — lung cancer remains the leading cause of cancer death globally.

TRIPLE LIPID-LOWERING THERAPY IN TYPE 2 DIABETES

  • Trial NCT07255820, registered June 26, 2026, is an open-label randomized trial comparing dual versus triple lipid-lowering therapy using rosuvastatin, ezetimibe, and bempedoic acid in type 2 diabetes patients with elevated LDL cholesterol — bempedoic acid inhibits ATP-citrate lyase upstream of statins.

HEART FAILURE MULTI-SCALE PHENOTYPING (MAP-HEART)

  • Trial NCT06280820 (MAP-HEART), registered June 26, 2026, is enrolling patients to compare blood and tissue samples across heart failure subtypes to better understand how HF develops; over 6.5 million Americans live with heart failure with over one million new diagnoses annually.

DOCETAXEL PLUS SX-682 IN HEAD AND NECK AND PROSTATE CANCER

  • Trial NCT07667400, registered June 26, 2026, combines docetaxel chemotherapy with SX-682 (a CXCR1/2 inhibitor targeting tumor-promoting myeloid cells) in recurrent/metastatic head and neck squamous cell carcinoma, salivary gland carcinoma, and advanced prostate cancer; survival rates below 50% for metastatic cases justify novel combinations.

mRNA VACCINE AGAINST RSV AND hMPV IN INFANTS (mRNA-1345/mRNA-1365)

  • Trial NCT05743881, updated June 26, 2026, is assessing safety and immunogenicity of Moderna's mRNA-1345 (RSV-targeting) and mRNA-1365 (RSV plus human metapneumovirus) mRNA vaccines in participants aged 5 months to under 24 months — both pathogens are leading causes of severe infant respiratory illness.

CORTISOL RHYTHM AND MILD AUTONOMOUS CORTISOL SECRETION - KETOCONAZOLE

  • Trial NCT07649317, registered June 26, 2026, is studying whether ketoconazole (a cortisol synthesis inhibitor) can normalize daily cortisol rhythms in Mild Autonomous Cortisol Secretion (MACS), a condition associated with hypertension, diabetes, and weight gain — all key accelerators of biological aging.

📢 PUBLIC HEALTH

LISTERIA - REQUESÓN/SOFT RICOTTA CHEESE

  • CDC issued a Listeria outbreak warning on June 5, 2026 linked to requesón/soft ricotta cheese; consumers are urged to check for and discard any implicated product.

INFANT BOTULISM - NARA ORGANICS POWDERED INFANT FORMULA

  • CDC's June 13, 2026 outbreak update urges parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula, linked to confirmed infant botulism cases.

NEW WORLD SCREWWORM - CDC EMERGENCY OPERATIONS CENTER ACTIVATED

  • CDC activated its Emergency Operations Center on June 12, 2026 for a New World Screwworm (Cochliomyia hominivorax) response — this parasitic fly larva can infest living tissue in humans and animals and has historically been eradicated from North America.

WHO - UNSAFE FOOD GLOBAL BURDEN

  • WHO reported on June 4, 2026 that unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide; children under five face nearly three times the illness risk from unsafe food compared with older individuals.

WHO PANDEMIC AGREEMENT - PATHOGEN ACCESS AND BENEFIT SHARING

  • WHO Director-General, in a June 15, 2026 open letter to leaders of G7, G20, and BRICS, urged nations to finalize the Pathogen Access and Benefit Sharing (PABS) annex to the WHO Pandemic Agreement, calling it unfinished essential global health architecture.

CDC TRAVELER-BASED GENOMIC SURVEILLANCE - 1 MILLION PARTICIPANTS

  • CDC announced January 30, 2026 that its Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants, enhancing CDC's capacity to detect novel or emerging pathogens entering the United States.

DRUG-RESISTANT BACTERIA SHARP RISE

  • A September 2025 CDC report found a dramatic increase in dangerous drug-resistant bacteria in the United States, reinforcing antimicrobial resistance as an accelerating public health threat.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda — WHO Disease Outbreak News
  2. Nipah virus disease - India — WHO Disease Outbreak News
  3. Yellow fever - Global — WHO Disease Outbreak News
  4. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  5. Epidemic of Ebola Disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda determined a pub — WHO News
  6. First meeting of the IHR Emergency Committee regarding the epidemic of Ebola Bundibugyo virus disease in the Democratic — WHO News
  7. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  8. WHO issues comprehensive guidelines on filovirus disease, including Ebola and Marburg disease — WHO News
  9. Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus — WHO News
  10. Enhanced Ebola Airport Screening Begins at Washington-Dulles International Airport — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260628-02-v14 · 2026-06-28 02:01 UTC

Read next